Business Barclays Downgrades Rapt Therapeutics to Equal Weight Amid Analyst Activity Barclays has downgraded shares of Rapt Therapeutics (NASDAQ:RAPT) from an overweight rating to an equal weight rating, according to a research note published on... Editorial24 January, 2026
Business BridgeBio Pharma Hits New 52-Week High as Analysts Boost Ratings Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) reached a new 52-week high of $78.47 during trading on Friday, October 30, 2023. The stock closed at... Editorial2 January, 2026